8-K: Shuttle Pharmaceuticals Advances Glioblastoma Trial with CRO Agreement and Site Activations

Shuttle Pharmaceuticals has engaged a contract research organization and activated two clinical sites to advance its Phase 2 trial of Ropidoxuridine for glioblastoma treatment.

Summary

• Shuttle Pharmaceuticals has entered into a work order with Theradex Systems, Inc., a contract research organization (CRO), to manage its Phase 2 clinical trial of Ropidoxuridine for glioblastoma.
• The CRO will oversee the 53-month study, including regulatory aspects and documentation, for a fee of approximately $2.3 million.
• The Phase 2 trial was approved by the FDA in January 2024 and the Institutional Review Board on June 21, 2024.
• Shuttle Pharma is in the process of signing up six clinical sites, with two sites having completed initial visits and one site ready to enroll patients.
• The company has also announced agreements with two of the six planned clinical trial locations.
• The Phase 2 trial will initially enroll 40 patients, randomized into two different doses, followed by an additional 14 patients on the optimal dose.
• The primary endpoint of the trial is survival compared to historical controls, and the company expects the trial to be completed in 18 to 24 months.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the progress of the clinical trial and the engagement of a CRO. However, the long timeline and the need for a change order for the budget temper the overall sentiment.

Positives

• The engagement of a CRO will streamline the management of the Phase 2 clinical trial.
• The FDA and Institutional Review Board approvals indicate regulatory progress.
• The activation of clinical sites marks a significant step forward in the trial.
• The Orphan Drug Designation provides potential marketing exclusivity upon FDA approval.
• The trial design includes an initial dose-finding phase followed by a larger cohort to achieve statistical significance.

Negatives

• The study is expected to take 53 months to complete, including long-term follow up, which is a long time for investors to wait for results.
• The initial budget of $2.237 million only covers the first year of the study, with a change order required for subsequent years.

Risks

• The clinical trial may not yield positive results, impacting the company's future prospects.
• The company may face challenges in enrolling the required number of patients.
• The study budget may increase beyond the initial estimates.
• There is a risk of delays in the trial timeline.
• The company is reliant on a single drug candidate, Ropidoxuridine.

Future Outlook

The company expects the Phase 2 clinical trial to be completed over a period of 18 to 24 months, with all six sites treating patients in the coming months.

Management Comments

• Anatoly Dritschilo, M.D., CEO, stated that the results of the trial will be important to the cancer community.
• Dr. Tyvin Rich, Chief Medical Officer, noted that the selected sites are likely to treat the target patient population, allowing for more rapid enrollment.

Industry Context

The announcement is relevant to the broader pharmaceutical industry, particularly in the field of oncology and radiation therapy. The development of radiation sensitizers is a growing area of interest, with the potential to improve cancer treatment outcomes. The company is targeting a specific subset of glioblastoma patients, which is a high unmet need.

Comparison to Industry Standards

• The use of a CRO like Theradex is standard practice in the pharmaceutical industry for managing clinical trials.
• The 53-month timeline for the study is typical for a Phase 2 trial with long-term follow-up.
• The initial budget of $2.237 million for the first year is within the expected range for a Phase 2 trial of this nature.
• Other companies developing radiation sensitizers include OncoMed Pharmaceuticals and Celldex Therapeutics, but they are not directly comparable as they are targeting different cancers or using different mechanisms of action.
• The trial design, including the initial dose-finding phase and subsequent expansion cohort, is a common approach in Phase 2 trials.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical trial and the potential for future revenue.
• Patients with glioblastoma may benefit from the development of a new treatment option.
• Employees of Shuttle Pharma will be involved in the execution of the clinical trial.
• The CRO, Theradex Systems, will benefit from the contract.

Next Steps

• Shuttle Pharma will continue to sign up the remaining clinical sites.
• Patient enrollment will commence at the activated sites.
• The company will monitor the progress of the trial and provide updates as needed.
• A change order will be required to cover the budget for the study beyond the first year.

Key Dates

Keywords

Glioblastoma, Ropidoxuridine, Clinical Trial, Phase 2, Radiation Sensitizer, Theradex Systems, CRO, Orphan Drug Designation, Brain Tumor, Radiation Therapy